MX2017004324A - Self-micellizing fatty acids and fatty acid ester compositions and their use in the treatment of disease states. - Google Patents

Self-micellizing fatty acids and fatty acid ester compositions and their use in the treatment of disease states.

Info

Publication number
MX2017004324A
MX2017004324A MX2017004324A MX2017004324A MX2017004324A MX 2017004324 A MX2017004324 A MX 2017004324A MX 2017004324 A MX2017004324 A MX 2017004324A MX 2017004324 A MX2017004324 A MX 2017004324A MX 2017004324 A MX2017004324 A MX 2017004324A
Authority
MX
Mexico
Prior art keywords
fatty acid
disease
compositions
omega
acid ester
Prior art date
Application number
MX2017004324A
Other languages
Spanish (es)
Inventor
Thorsteinsson Thorsteinn
D Sancilio Frederick
DANIEL-ARCHIBALD Glynis
Lopez-Toledano Miguel
Abd Almalik Ahmed Mohammed Daak Ahmed
Original Assignee
Sancilio & Company Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54347886&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2017004324(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sancilio & Company Inc filed Critical Sancilio & Company Inc
Publication of MX2017004324A publication Critical patent/MX2017004324A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/32—Manganese; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Described herein are compositions including at least one omega-3 fatty acid (either in the triglyceride, ester or free fatty acid ester form) and at least one surface active agent; wherein the compositions form micelles when in contact with an aqueous medium. Also provided are methods of administering to a subject a composition including at least one omega-3 fatty acid (either in the triglyceride, ester or free fatty acid ester form) and at least one surface active agent, wherein the compositions form micelles when in contact with an aqueous medium, and the bioavailability of the omega-3 fatty acid is substantially independent of a food effect. The compositions are useful for treating certain disease states which may include (1) malabsorption syndromes, (2) primary sclerosing cholangitis (PSC), (3) non-alcoholic fatty liver disease (NAFLD), (4) sickle cell disease (SCD), (5) age-related macular degeneration (AMD), and (6) neurodegenerative disease, including, Parkinson's Disease (PD), Alzheimer's Disease (AD), Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease), Epilepsy, Bi-polar Syndrome, traumatic brain injury, peripheral neuropathy, and Multiple Sclerosis (MS). Described are also various dosage forms for administering the compositions and use of the compositions in functional foods. Provided herein are also kits with instructions for their administration.
MX2017004324A 2014-10-10 2015-10-09 Self-micellizing fatty acids and fatty acid ester compositions and their use in the treatment of disease states. MX2017004324A (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201462062638P 2014-10-10 2014-10-10
US201462062634P 2014-10-10 2014-10-10
US201462062646P 2014-10-10 2014-10-10
US201462062651P 2014-10-10 2014-10-10
US201462062643P 2014-10-10 2014-10-10
US201462062652P 2014-10-10 2014-10-10
PCT/US2015/054933 WO2016057915A1 (en) 2014-10-10 2015-10-09 Self-micellizing fatty acids and fatty acid ester compositions and their use in the treatment of disease states

Publications (1)

Publication Number Publication Date
MX2017004324A true MX2017004324A (en) 2017-07-04

Family

ID=54347886

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017004324A MX2017004324A (en) 2014-10-10 2015-10-09 Self-micellizing fatty acids and fatty acid ester compositions and their use in the treatment of disease states.
MX2020002238A MX2020002238A (en) 2014-10-10 2017-04-03 Self-micellizing fatty acids and fatty acid ester compositions and their use in the treatment of disease states.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2020002238A MX2020002238A (en) 2014-10-10 2017-04-03 Self-micellizing fatty acids and fatty acid ester compositions and their use in the treatment of disease states.

Country Status (8)

Country Link
EP (1) EP3212236A1 (en)
BR (1) BR112017007428A2 (en)
CA (1) CA2963952C (en)
CL (1) CL2017000867A1 (en)
MA (1) MA40846A (en)
MX (2) MX2017004324A (en)
WO (1) WO2016057915A1 (en)
ZA (1) ZA201702385B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106692973A (en) * 2015-11-13 2017-05-24 深圳君圣泰生物技术有限公司 Pharmaceutical compositions and applications thereof, and pharmaceutical preparation
EP3456328A4 (en) * 2016-05-10 2020-02-26 Shenzhen Hightide Biopharmaceutical., Ltd. Composition, and application and pharmaceutical preparation thereof
US11241408B2 (en) 2016-08-12 2022-02-08 Pharmako Biotechnologies Pty Limited Omega-3 compositions and methods relating thereto
FR3092968B1 (en) * 2019-02-22 2021-05-21 Microphyt DIETARY SUPPLEMENT
IT201900007202A1 (en) * 2019-05-24 2020-11-24 Pavia Farm S R L COMPOSITION BASED ON LIPOSOLUBLE VITAMINS WITH HIGH ENTERIC ABSORPTION
WO2021028737A1 (en) 2019-08-13 2021-02-18 Team Foods Colombia S.A. Lipid composition comprising antioxidants and natural polyphenols as a non-pharmacological alternative for the treatment and prevention of non-alcoholic fatty liver disease (nafld)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5313343B2 (en) * 2009-05-22 2013-10-09 持田製薬株式会社 Self-emulsifying composition of ω3 fatty acid
WO2012032414A2 (en) * 2010-09-08 2012-03-15 Pronova Biopharma Norge As Compositions comprising a fatty acid oil mixture, a surfactant, and a statin
EP2793867B1 (en) * 2011-12-22 2021-01-20 Baes, Erik Gelatin/alginate delayed release capsules comprising omega-3 fatty acids, and methods and uses thereof
WO2013148136A1 (en) * 2012-03-30 2013-10-03 Sancilio & Company, Inc. Omega-3 fatty acid ester compositions

Also Published As

Publication number Publication date
MA40846A (en) 2017-09-05
CL2017000867A1 (en) 2017-11-03
EP3212236A1 (en) 2017-09-06
MX2020002238A (en) 2020-07-13
ZA201702385B (en) 2020-12-23
CA2963952A1 (en) 2016-04-14
WO2016057915A1 (en) 2016-04-14
BR112017007428A2 (en) 2017-12-19
CA2963952C (en) 2023-10-17

Similar Documents

Publication Publication Date Title
MX2020002238A (en) Self-micellizing fatty acids and fatty acid ester compositions and their use in the treatment of disease states.
IN2014DN08449A (en)
TN2018000121A1 (en) Valbenazine salts and polymorphs thereof
AU2016343803A8 (en) Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
PH12014501750A1 (en) Pharmaceutical compositions containing dimethyl fumarate
WO2014004861A3 (en) Methods of treating pediatric metabolic syndrome
MX2018000179A (en) Solid forms and formulations of (s)-4-(8-amino-3-(1 -(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(py ridin-2-yl)benzamide.
WO2016134223A3 (en) Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereof
MX2012012225A (en) Nitric oxide releasing prodrugs of therapeutic agents.
NZ618734A (en) Polyunsaturated fatty acids for the treatment of diseases related to cardiovascular, metabolic and inflammatory disease areas
MX2015002239A (en) Ophthalmic formulation of polyoxyl lipid or polyoxyl fatty acid and treatment of ocular conditions.
NZ596228A (en) Compositions and methods for the treatment of inflammation
NZ709803A (en) Compositions comprising 15-ohepa and methods of using the same
WO2014107730A3 (en) Use of fatty acid niacin conjugates for treating diseases
BR112016024020A8 (en) pharmaceutical composition
PH12019500618A1 (en) Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease
CY1123942T1 (en) OMEGA-3 FATTY ACID COMPOSITIONS FOR THE TREATMENT OF DISEASES CAUSING DAMAGE TO THE NERVOUS SYSTEM
NZ718185A (en) Pharmaceutical composition containing verbenone derivative for treating or preventing neurodegenerative disease
WO2011143271A3 (en) Therapeutic liposomes and methods for producing and using the same
WO2018093237A3 (en) Composition comprising formic acid or pharmaceutically acceptable salt thereof as active ingredient for preventing or treating obesity or metabolic syndromes caused by obesity
MX2019003365A (en) Lipoic acid choline ester compositions and methods to stabilize into pharmaceutically relevant drug products.
JOP20180071A1 (en) CJ Healthcare Corporation
MX2016013680A (en) Methods and compositions for treatment of lipid storage disorders.
EA202191683A1 (en) PRODUCT CONTAINING 4-PHENYLBUTYRATE FOR PREVENTION OR TREATMENT OF PRESBIOPIA
WO2014073946A3 (en) Use of betalains and derivatives thereof for the production of a drug for the treatment, prevention, regulation and control of hepatopathies, diseases with inflammatory infiltrate, necrosis and for the modificaiton of lipid deposits